New Targeted Therapies and Emerging Data in Urothelial Carcinoma

Review expert guidance on integrating erdafitinib and enfortumab vedotin into management of progressive urothelial carcinoma, then get up to date on key data for sacituzumab govitecan and other promising investigational therapies.
Petros Grivas, MD, PhD
Format: Microsoft PowerPoint (.ppt)
File Size: 3.29 MB
Released: February 26, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Immunomedics, Inc.

Related Content

Slides from Arjun Balar, MD on the role of biomarkers in managing urothelial cancer, from Clinical Care Options (CCO)

person default Arjun Balar, MD Released: April 21, 2021

Get expert insight from Arjun Balar, MD on the role of biomarkers in managing urothelial or bladder cancer, from Clinical Care Options (CCO)

person default Arjun Balar, MD person default Kaitlynn Francese, MSN, RN, OCN Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: April 21, 2021 Expired: April 20, 2022

Prof. Dr. Arndt Hartmann, Prof. Dr. Arndt Hartmann has disclosed that he has received consulting fees from Agilent, AstraZeneca, Bristol-Myers Squibb, Diaceutics, Janssen, MSD, Pfizer, and Roche. Released: April 9, 2021

CCO downloadable PDF: Targeting FGFR in urothelial cancer and other malignancies

Alison Birtle, MD, FRCP, FRCR person default Ignacio Duran, MD, PhD Released: April 1, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue